News

iTHRIV Announces Health Research Pilot Project Recipients

The Clinical and Translational Science Award (CTSA) hub partnership between Virginia Tech, the University of Virginia, Carilion Clinic, and Inova Health System has awarded $200,000 in funding to five research projects through the Pilot Translational and Clinical Studies Program. Multi-institutional teams of scientists, physicians, and engineers will study Parkinson’s disease, celiac disease, pediatric heart transplant, pediatric telemedicine, and epilepsy.

Locally, the CTSA partners administer the grants through the integrated Translational Health Research Institute of Virginia (iTHRIV). iTHRIV is funded by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, through award number UL1TR003015.

The awarded pilot projects include:

Studying auditory therapy for Parkinson’s disease

Della Williams, a neurologist at Carilion Clinic and an assistant professor of internal medicine at the Virginia Tech Carilion School of Medicine, and Sujith Vijayan, an assistant professor in the Virginia Tech College of Science’s School of Neuroscience, are studying if patients with Parkinson’s disease can benefit from background noise during sleep.

Designing an interactive training system for pediatric telemedicine cart operations incorporating augmented reality

Elham Morshedzadeh, an assistant professor of industrial design in Virginia Tech’s College of Architecture and Urban Studies; Andre Muelenaer, a professor of practice in Virginia Tech’s College of Engineering, a professor of pediatrics for the Virginia Tech Carilion School of Medicine, and a pediatric pulmonologist at Carilion; Wallace Lages, an assistant professor in the School of Visual Arts; and Melinda Schriver, Carilion’s director of digital health, are designing a robust and affordable training program to help improve telemedicine encounters for infants and pre-school children.

Measuring medication in patients with epilepsy

Aashit Shah, Carilion’s chief of neurology and a professor of internal medicine at the Virginia Tech Carilion School of Medicine, and Sujith Vijayan will analyze intracranial electrical signals in epilepsy patients to help identify which brain regions are affected by certain neuroactive drugs.

Searching for genetic markers for celiac disease with machine learning

Sana Syed, an assistant professor in the UVA School of Medicine’s department of pediatrics, and Suchitra Hourigan, Inova Children’s Hospital’s vice chair of research and innovation, are studying gut tissue biopsies and genetic markers from patients diagnosed with celiac disease, to assess the risk of these patients developing other diseases, including type 1 diabetes and hypothyroidism.

Defining donor characteristics for pediatric heart transplants

Heart transplantation is the standard of care for pediatric patients with end-stage heart failure or inoperable congenital defects, yet nearly 20 percent of patients with these conditions die while on the waitlist. To help increase the odds of successful pediatric heart transplants, Michael McCulloch, an associate professor and a pediatric cardiologist at UVA Children’s Hospital Heart Center, and Michael Porter, an associate professor of systems engineering in UVA’s School of Engineering and Applied Science, will anlayze donor echocardiographic data to identify which donor characteristics contribute to positive heart transplant recipient outcomes.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the